New Transcriptomic Biomarkers for Detection of the Recombinant Human Erythropoietin (rHuEPO) MirCERA in Horses
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3812 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Benoit Loup und 8 weiteren Autor:innen. Beteiligte Einrichtung: GIE LCH, Laboratoire des Courses Hippiques, Verrières-le-Buisson, France. Hauptthemen laut MEDLINE: Erythropoietin, Substance Abuse Detection, Transcriptome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Institut Français du Cheval et de l'Equitation.
Abstract (Originalsprache)
Detection and monitoring of biomarkers related to doping is particularly suitable for the development of analytical strategies dedicated to indirect detection of banned substances. Previous studies in horses have already allowed the investigation of transcriptomic biomarkers in equine blood associated with reGH and rHuEPO administrations. Our most recent developments continue to focus on the discovery and monitoring of transcriptomic biomarkers for the control of ESAs, and a collaborative study with WADA‐accredited doping control laboratories has recently been initiated to conduct a pilot study. In humans, three mRNAs (ALAS2, CA1, and SLC4A1) were previously observed to be differentially expressed after blood doping and were associated with immature red blood cells, the so‐called circulating reticulocytes. In horses, circulating reticulocytes are rarely observed even after rHuEPO administration. With the improved primers that detect the equine orthologues of the human mRNAs from the ALAS2, CA1, and SLC4A1 genes, we can now report the first evidence of the detection of the three biomarkers in equine blood. In addition, an upregulation of the mRNA levels of the three genes was observed after analysis of blood samples collected from MirCERA‐treated animals, with kinetics similar to those previously documented in humans. Our data suggest that ALAS2 and CA1 are promising indirect biomarkers for the detection of recombinant EPO abuse in horses, as observed in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GIE LCH, Laboratoire des Courses Hippiques, Verrières-le-Buisson, France.
- Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Laboratoire antidopage français (LADF), Université Paris-Saclay, Orsay, France.
ORCID-Profile: Benoit Loup, Nicolas Leuenberger, Alexandre Marchand, Agnès Barnabé, Vivian Delcourt, Patrice Garcia, Marie-Agnès Popot, Ludovic Bailly-Chouriberry
Förderung
- Institut Français du Cheval et de l'Equitation
Zitieren
APA
Loup, B., André, F., Leuenberger, N., Marchand, A., Barnabé, A., Delcourt, V., Garcia, P., Popot, M. A., & Bailly-Chouriberry, L. (2025). New Transcriptomic Biomarkers for Detection of the Recombinant Human Erythropoietin (rHuEPO) MirCERA in Horses. Drug Testing and Analysis. https://doi.org/10.1002/dta.3812
Vancouver
Loup B, André F, Leuenberger N, Marchand A, Barnabé A, Delcourt V, et al. New Transcriptomic Biomarkers for Detection of the Recombinant Human Erythropoietin (rHuEPO) MirCERA in Horses. Drug Testing and Analysis. 2025. doi:10.1002/dta.3812
BibTeX
@article{Loup2025,
author = {Loup, Benoit and André, François and Leuenberger, Nicolas and Marchand, Alexandre and Barnabé, Agnès and Delcourt, Vivian and Garcia, Patrice and Popot, Marie-Agnès and Bailly-Chouriberry, Ludovic},
title = {New Transcriptomic Biomarkers for Detection of the Recombinant Human Erythropoietin (rHuEPO) MirCERA in Horses},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3812}
}
EUVIMED